Smith-Lemli-Opitz syndrome (SLOS) is an inherited cholesterol metabolism disorder caused by pathogenic variants in the DHCR7 gene. It is inherited in an autosomal recessive pattern and is due to a deficiency of the enzyme 7-dehydrocholesterol reductase, which reduces cholesterol synthesis and leads to the accumulation of 7-dehydrocholesterol, a potentially toxic precursor.
Smith-Lemli-Opitz Syndrome
The DHCR7 gene encodes the enzyme 7-dehydrocholesterol reductase, responsible for the last step of cholesterol biosynthesis, in which 7-dehydrocholesterol (7-DHC) is converted into cholesterol. Cholesterol is essential for the formation of cell membranes, the synthesis of steroid hormones, the production of bile acids, myelination, and embryonic development, especially of the nervous system.
When pathogenic variants exist in DHCR7, enzymatic activity decreases variably or may be practically absent. This leads to a combination of cholesterol deficiency and accumulation of 7-DHC and other precursor sterols, which interfere with key processes of development and cell function.
The clinical consequence is a highly variable multisystemic spectrum, from severe prenatal or neonatal forms to milder presentations with dysmorphic features, developmental abnormalities, and behavioral problems. SLOS is transmitted with autosomal recessive inheritance, meaning an affected person typically inherits two pathogenic variants, one from each parent. Its incidence is estimated at approximately 1 in 20,000 to 60,000 live births, with a higher frequency described in populations of European ancestry.
Symptoms
The onset of SLO is congenital, although severity can vary widely. The most characteristic findings include prenatal or postnatal growth retardation, microcephaly, hypotonia, developmental delay or intellectual disability, distinctive facial features, feeding difficulties, photophobia or photosensitivity, and syndactyly of the second and third toes. In males, genital anomalies such as hypospadias or ambiguous genitalia may occur.
Cardiac, renal, gastrointestinal, or palate malformations, as well as behavioral disorders, autism spectrum traits, irritability, or sleep disturbances may also be present.
Disease management
The management of Smith-Lemli-Opitz syndrome is primarily supportive and should be adapted to clinical severity. Dietary supplementation with cholesterol, through cholesterol-rich foods or specific preparations, may improve some biochemical parameters and support growth, although it does not completely correct developmental manifestations.
Feeding difficulties, congenital malformations, photosensitivity, behavioral changes, and neurological, ophthalmological, cardiac, or endocrine complications should be treated individually. The use of statins, such as simvastatin, has been studied to reduce 7-DHC levels in selected cases, but requires specialized evaluation and close monitoring, as it is not an established curative therapy.
Genes analyzed
Bibliography
Nowaczyk MJM, Wassif CA. Smith-Lemli-Opitz Syndrome. 1998 Nov 13 [updated 2020 Jan 30]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
Kritzer A, Dutta R, Pramparo T, et al. Smith-Lemli-Opitz syndrome: Clinical, biochemical, and genetic insights with emerging treatment opportunities. Genet Med. 2025 Jul;27(7):101450. Epub 2025 Apr 29.
Donoghue SE, Pitt JJ, Boneh A, et al. Smith-Lemli-Opitz syndrome: clinical and biochemical correlates. J Pediatr Endocrinol Metab. 2018 Mar 28;31(4):451-459.
